Clinical trial
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To…
NCT00085904 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00085904 |
|---|---|
| Title | Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas |
| Official title | A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients With Solid Tumors and Lymphomas |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Cancer, Lymphoma |
| Intervention type | Drug |
| Interventions | SB-485232 |
| Enrollment | 12 |
| Start date | Apr 1, 2004 |
| First posted | Jun 18, 2004 |
| Last update posted | Oct 13, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: